Roca M, Baca E, Prieto R, García-Calvo C
Institut Universitari d'Investigació en Ciències de la Salut, Hospital Juan March, Universitat de les Illes Balears, Spain.
Actas Esp Psiquiatr. 2008 Mar-Apr;36(2):82-9.
The primary objectives of this study are to evaluate gender-specific differences in the clinical profile of primary care depressive patients as well as in the clinical response and remission to venlafaxine extended release.
We have analyzed a sample of 6,719 adult outpatients (1,713 men and 4,925 women) with diagnosis of depressive syndrome with associated anxiety symptoms included in an observational, prospective, multicenter and open study. Venlafaxine extended release was administered for 24 weeks at a dosage of 75-225 mg/day.
In this study we have not found overall differences regarding the baseline severity of the depressive episode, as assessed by means of the HAM-D17 and Clinical Global Impression Scale of Severity (CGI-S). However, women showed higher scores on items of the HAM-D17 and HAM-A scales related with anxious and somatic complaints at baseline and endpoint. The percentage of remission on the HAM-D17 scale reached 75.4 % for men and 74.3 % for women (p = 0.4339) at week 24. In the case of HAM-A: 84.1% vs. 80.6% (men vs. women, p=0.004).
We did not observe baseline differences in the mean score of the HAM-D17 nor the remission rates between women and men (HAM-D17) at the final visit. Women showed lower anxiety remission rates (HAM-A) and maintained more anxious and somatic complaints throughout the study.
本研究的主要目的是评估初级保健抑郁症患者临床特征中的性别差异，以及对文拉法辛缓释剂的临床反应和缓解情况。
我们分析了6719名成年门诊患者（1713名男性和4925名女性）的样本，这些患者被诊断为伴有焦虑症状的抑郁综合征，该样本纳入了一项观察性、前瞻性、多中心开放研究。文拉法辛缓释剂以75 - 225毫克/天的剂量给药24周。
在本研究中，通过汉密尔顿抑郁量表17项（HAM - D17）和临床总体印象严重程度量表（CGI - S）评估，我们未发现抑郁发作基线严重程度存在总体差异。然而，在基线和终点时，女性在HAM - D17和HAM - A量表中与焦虑和躯体主诉相关的项目上得分更高。在第24周时，男性在HAM - D17量表上的缓解率达到75.4%，女性为74.3%（p = 0.4339）。在HAM - A量表方面：男性为84.1%，女性为80.6%（p = 0.004）。
我们在最终访视时未观察到女性和男性在HAM - D17平均得分或缓解率（HAM - D17）方面存在基线差异。女性的焦虑缓解率（HAM - A）较低，且在整个研究过程中保持着更多的焦虑和躯体主诉。
